Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ravulizumab

(RAV-yoo-LIZ-yoo-mab)
A drug used to treat adults with paroxysmal nocturnal hemoglobinuria (a rare red blood cell disorder) and adults and children aged 1 month and older with atypical hemolytic uremic syndrome (a very rare disorder in which tiny blood clots form in small blood vessels). It is also being studied in the treatment of other conditions. Ravulizumab binds to an immune system protein called C5. This may help keep red blood cells from breaking down and blood clots from forming. Ravulizumab is a type of monoclonal antibody. Also called Ultomiris.
More Information
Search NCI's Dictionary of Cancer Terms